Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Payables (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Payables for 15 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 51.69% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Sep 2025, up 51.69%, and an annual FY2024 reading of $3.2 million, down 14.21% over the prior year.
  • Payables was $5.9 million for Q3 2025 at Fennec Pharmaceuticals, down from $5.9 million in the prior quarter.
  • Across five years, Payables topped out at $5.9 million in Q2 2025 and bottomed at $677000.0 in Q2 2021.
  • Average Payables over 5 years is $3.3 million, with a median of $3.0 million recorded in 2023.
  • The sharpest move saw Payables tumbled 75.43% in 2021, then soared 157.46% in 2022.
  • Year by year, Payables stood at $1.2 million in 2021, then soared by 107.11% to $2.4 million in 2022, then skyrocketed by 58.08% to $3.8 million in 2023, then dropped by 14.21% to $3.2 million in 2024, then surged by 80.99% to $5.9 million in 2025.
  • Business Quant data shows Payables for FENC at $5.9 million in Q3 2025, $5.9 million in Q2 2025, and $5.3 million in Q1 2025.